Clinical outcomes and risk factors for local failure and visual impairment in patients treated with Ru-106 brachytherapy for uveal melanoma
Open Access
- 24 February 2025
- journal article
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 52, 100939
Abstract
No abstract availableKeywords
Funding Information
- Dutch Cancer Society
- Varian Medical Systems
- Philips Oral Healthcare
This publication has 43 references indexed in Scilit:
- Ruthenium-106 brachytherapy and central uveal melanomaInternational Ophthalmology, 2025
- MR-based follow-up after brachytherapy and proton beam therapy in uveal melanomaNeuroradiology, 2023
- Complex heatmap visualizationiMeta, 2022
- Ruthenium brachytherapy for uveal melanomas: Factors affecting the development of radiation complicationsBrachytherapy, 2018
- Clinical evaluation of ultra-high-field MRI for three-dimensional visualisation of tumour size in uveal melanoma patients, with direct relevance to treatment planningMagnetic Resonance Materials in Physics, Biology and Medicine, 2016
- Ward’s Hierarchical Agglomerative Clustering Method: Which Algorithms Implement Ward’s Criterion?Journal of Classification, 2014
- The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal MelanomaArchives of Ophthalmology (1950), 2006
- Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years’ experience with beta-rays)American Journal of Ophthalmology, 2004
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996
- Rates of local control, metastasis, and overall survival in patients with posterior uveal melanomas treated with ruthenium-106 plaquesRadiotherapy and Oncology, 1993